Dogwood (DWTX) Therapeutics announces the dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP, evaluating Halneuron for the treatment of neuropathic pain associated with prior chemotherapy treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX: